Find Funding Opportunities

Find Funding Opportunities

Returning 1310 results

Clinical and Biological Measures of TBI-related dementia including Chronic Traumatic Encephalopathy (CTE) (R01 Clinical Trial Not Allowed)

RFA
Monday, February 25, 2019
Tuesday, April 16, 2019
R01
RFA-NS-19-026

Funding Opportunity Purpose

This FOA invites investigation of biological and clinical measures of TBI-related progressive neurodegeneration and neurocognitive decline associated with increased risk for dementia and /or traumatic encephalopathy syndrome (TES) (clinicopathologic diagnostic counterpart to the neuropathological diagnosis of Chronic Traumatic Encephalopathy (CTE)). The overall goal is to advance knowledge of the underlying pathophysiology and clinical characterization of the chronic effects of TBI that distinguish static-chronic TBI cognitive impairment from those that lead to progressive neurodegeneration associated with TES and dementia. Investigations should be conducted in existing, well-characterized populations of patients with a history of TBI, enriched for increased risk of cognitive impairment or dementia, that have been and can continue to be followed longitudinally. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in this area.

Neuropathological Assessment of TBI-related Neurodegeneration and Neurocognitive decline - Center Without Walls (NATBI CWOW) (U54 Clinical Trial Not Allowed)

RFA
Monday, February 25, 2019
Tuesday, April 16, 2019
U54
RFA-NS-19-030

Funding Opportunity Purpose

This FOA invites applications for a multisite study to comprehensively characterize the neuropathological features associated with neurodegeneration and neurocognitive decline in persons with a history of traumatic brain injury (TBI). Investigations should elucidate the contribution of key individual (sex, age at time of injury, time since injury, etc) and injury characteristics (injury severity and frequency) to describe associations between neuropathological burden and antemortem clinicopathologic symptoms, and outline the prevalence of TBI-related parkinsonism, TBI-related Alzheimers, and CTE in the participating brain banks. To further advance research in the area, broad sharing of clinical and neuropathological data will be a critical feature of this FOA including the development of a digital resource for distribution and sharing of assessed neuropathological tissue.

Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States Including in Health Disparities Populations (U19 Clinical Trial not Allowed)

RFA
Friday, February 15, 2019
Thursday, April 18, 2019
U19
RFA-NS-19-012

Funding Opportunity Purpose

The National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA) intend to publish a Funding Opportunity Announcement (FOA) to solicit applications for a large prospective clinical research study to determine the specific subsets of stroke events that predict cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations, and what additional clinical factors and comorbidities along the AD/ADRD spectrum may causally synergize with stroke to result in (or prevent) cognitive impairment and dementia outcomes. The goals of this initiative are to determine the association between specific subsets of stroke events and subsequent cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations; to identify additional clinical factors and comorbidities that may affect these associations; and to contribute to development and validation of clinical-trial ready diagnostic and progression biomarkers for post-stroke dementia. It is expected that the study design will also allow for determination of interrelationships (cross-sectional and longitudinal) among the stroke event, overall cerebrovascular and cardiovascular disease and risk factors (including sex, racial, and ethnic differences), dementia-relevant genetic variants (including ApoE) and mutations (e.g. in Notch 3) previously associated with Alzheimer's disease (e.g. APP, PS1, PS2, PICALM, CLU, TREM2), cognitive trajectories including decline and resistance to decline, as well as amyloid and tau biomarkers of Alzheimers pathology during life.

Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (PCS-EMA CWOW) (U54 Clinical Trial Not Allowed)

RFA
Thursday, February 7, 2019
Thursday, April 11, 2019
U54
RFA-NS-19-022

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) is aimed at discovering, determining the selectivity and sensitivity, and externally validating biological measures to be used for assessing, prognosing and monitoring recovery of youth who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in children ages 9 - 14.

Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trials Required)

RFA
Tuesday, February 5, 2019
Friday, March 15, 2019
R61/R33
RFA-OD-19-018

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. The total project period for an application submitted in response to this FOA may not exceed five years. This FOA provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition of up to four years of expanded clinical trial support (R33), although the total duration of the award may not exceed five years. This FOA requires measurable R61 milestones.

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed)

RFA
Tuesday, February 5, 2019
Friday, March 15, 2019
R21
RFA-OD-19-015

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in Down syndrome. The initiative seeks applications that are intended to facilitate Down syndrome research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials for Down syndrome and its co-occurring conditions, and to increase their likelihood of success through development and testing of biomarkers and clinical outcome assessment measures, development and testing of novel trial methods and recruitment strategies, or by defining the presentation and course of the co-occurring conditions in individuals with Down syndrome to enable the design of future clinical trials.

Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)

RFA
Tuesday, February 5, 2019
Friday, March 15, 2019
R01
RFA-OD-19-016

Funding Opportunity Purpose

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project is soliciting applications for this Request for Applications (RFA) for Transformative R01 to support individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Applications from individuals with diverse backgrounds and in any topic relevant to Down syndrome research are welcome. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to produce a major impact in research related to Down syndrome.

Human Three-Dimensional Cell Model Systems for Alzheimer's Disease-Related Dementias (ADRDs) (UG3/UH3 Clinical Trial Not Allowed)

RFA
Tuesday, January 29, 2019
Friday, March 15, 2019
UG3/UH3
RFA-NS-19-027

Funding Opportunity Purpose

This FOA invites applications that propose to develop, characterize and validate innovative human cellular model systems that recapitulate phenotypic, mechanistic and neuropathological hallmarks of Alzheimers Disease-Related Dementias (ADRDs). Model systems will be expected to capture the complex, multi-faceted proteinopathies and/or vascular pathology observed in ADRDs, with multiple cell types represented in each model. Years 3-5 will focus on the extensive characterization and perturbation of the cellular model systems. The overall goal of this FOA is to establish next generation human cellular model systems for ADRDs to serve as tools to interrogate molecular disease mechanisms and identify potential therapeutic targets.

Human Three-Dimensional Cell Model Systems for Alzheimers Disease-Related Dementias (ADRDs) (UG3/UH3 Clinical Trial Not Allowed)

RFA
Tuesday, January 29, 2019
Friday, March 15, 2019
UG3/UH3
RFA-NS-19-027

Funding Opportunity Purpose

This FOA invites applications that propose to develop, characterize and validate innovative human cellular model systems that recapitulate phenotypic, mechanistic and neuropathological hallmarks of Alzheimers Disease-Related Dementias (ADRDs). Model systems will be expected to capture the complex, multi-faceted proteinopathies and/or vascular pathology observed in ADRDs, with multiple cell types represented in each model. Years 3-5 will focus on the extensive characterization and perturbation of the cellular model systems. The overall goal of this FOA is to establish next generation human cellular model systems for ADRDs to serve as tools to interrogate molecular disease mechanisms and identify potential therapeutic targets.

Development and Validation of Advanced Mammalian Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)

PAR
Wednesday, January 23, 2019
Friday, March 15, 2019
R61/R33
PAR-19-167

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages research to develop, characterize and validate innovative mammalian models that recapitulate molecular, cellular, neuropathological, behavioral and cognitive hallmarks of the Alzheimers Disease-Related Dementias (ADRD), including Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), frontotemporal degeneration (FTD) and mixed etiology dementias (MED). Models will be expected to exhibit a broad range of features characteristic of the dementia disorder being modeled, including a mid- to late-life onset consistent with the human disorder, multiple age-dependent neuropathological processes and the associated behavioral, cognitive and/or physiological abnormalities. For each proposed mammalian model, a relevant suite of phenotypes that inform human ADRD disease progression and mechanisms should be characterized across the full life span or, for longer-living mammalian models, throughout the disease-relevant stages of adulthood. The goal of this FOA is to establish multi-dimensional mammalian models for ADRD to serve as tools to interrogate molecular disease mechanisms and identify therapeutic targets.

Pages